Trial Profile

Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emicizumab (Primary) ; Efmoroctocog alfa
Indications Haemophilia A
Focus Therapeutic Use

Most Recent Events

06 Jul 2022 Status changed from recruiting to discontinued.
04 Oct 2021 Planned initiation date changed from 1 Jul 2021 to 1 Nov 2021.
02 Sep 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2021 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com